BioCryst Appoints Steve Frank to Board of Directors

Core Insights - BioCryst Pharmaceuticals has appointed Steve Frank, a leader in healthcare investment banking, to its board of directors, enhancing its strategic capabilities in the biopharma sector [1][3]. Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on developing innovative therapies for rare diseases, leveraging expertise in structure-guided drug design [6]. - The company has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies [6]. Leadership and Expertise - Steve Frank has extensive experience in healthcare investment banking, previously serving as chairman of global healthcare investment banking at J.P. Morgan and leading Bear Stearns' healthcare investment banking before its acquisition [2]. - His background includes directing State Farm's multi-billion-dollar life science equity portfolio in the 1980s and 1990s, showcasing his investment acumen [2]. Strategic Positioning - BioCryst is positioned for growth with a commercial product nearing $1 billion in peak sales and a strong cash position that allows independence from capital markets [4]. - The company is focused on accelerating towards profitability while advancing its pipeline of potential best-in-class medicines [4].